Compounds > 4,4'-diaminobenzanilide
Page last updated: 2024-12-06

4,4'-diaminobenzanilide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4,4'-diaminobenzanilide: not carcinogenic [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID69917
CHEMBL ID350416
SCHEMBL ID137276
MeSH IDM0104515

Synonyms (47)

Synonym
nsc-37092
785-30-8
4-aminobenzoyl-4'-aminoanilide
benzamide, 4-amino-n-(4-aminophenyl)-
benzanilide,4'-diamino-
nsc37092
4,4'-diaminobenzanilide
4-amino-n-(4-aminophenyl)benzamide
p,p'-diaminobenzanilide
einecs 212-321-5
nsc 37092
benzanilide, 4,4'-diamino-
OPREA1_697167
4,4'-diaminobenzanilide, 98%
STK396695
CHEMBL350416
D2005
AKOS001037988
4-amino-n-(4-aminophenyl)benzamide;
A839439
BBL004104
00x4jm89uh ,
unii-00x4jm89uh
ccris 8916
dtxcid40400
NCGC00258270-01
dtxsid4020400 ,
tox21_200716
cas-785-30-8
FT-0616994
n-(4-aminophenyl)-4-aminobenzamide
diaminobenzanilide, 4,4'-
SCHEMBL137276
4,4'-diamino benzanilide
4-amino-n-(4-amino-phenyl)-benzamide
W-104276
4-amino-n-(4-aminophenyl)benzamide #
mfcd00025361
sr-01000363561
SR-01000363561-1
F10214
DS-14634
EN300-16815
Q27231382
4,4'-diaminobenzanilide (daba)
CS-W013005
Z56785539
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency39.98000.007215.758889.3584AID1224835
RAR-related orphan receptor gammaMus musculus (house mouse)Potency11.44100.006038.004119,952.5996AID1159521; AID1159523
AR proteinHomo sapiens (human)Potency51.40450.000221.22318,912.5098AID1259243; AID743042; AID743054
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency15.37090.000657.913322,387.1992AID1259377
progesterone receptorHomo sapiens (human)Potency38.61000.000417.946075.1148AID1346784
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency3.11140.003041.611522,387.1992AID1159552; AID1159553; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency61.19270.001530.607315,848.9004AID1224849
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency68.65940.001723.839378.1014AID743083
Histone H2A.xCricetulus griseus (Chinese hamster)Potency63.66320.039147.5451146.8240AID1224845
histone deacetylase 9 isoform 3Homo sapiens (human)Potency27.33380.037617.082361.1927AID1259364; AID1259388
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID446991Anticonvulsant activity in CF1 albino mouse assessed as inhibition of maximal electric shock-induced seizure at 100 mg/kg, ip after 0.5 hrs2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID446996Anticonvulsant activity in Sprague-Dawley rat assessed as inhibition of maximal electric shock-induced seizure at 30 mg/kg, po after 0.25 hrs2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID446994Anticonvulsant activity in CF1 albino mouse assessed as inhibition of maximal electric shock-induced seizure at 100 mg/kg, ip after 4 hrs2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID446990Anticonvulsant activity in CF1 albino mouse assessed as inhibition of maximal electric shock-induced seizure at 30 mg/kg, ip after 0.5 hrs2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID446998Anticonvulsant activity in Sprague-Dawley rat assessed as inhibition of maximal electric shock-induced seizure at 30 mg/kg, po after 1 hrs2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID446995Anticonvulsant activity in CF1 albino mouse assessed as inhibition of maximal electric shock-induced seizure at 300 mg/kg, ip after 4 hrs2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID446997Anticonvulsant activity in Sprague-Dawley rat assessed as inhibition of maximal electric shock-induced seizure at 30 mg/kg, po after 0.5 hrs2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID447144Neurotoxicity in Sprague-Dawley rat at 500 mg/kg, po by positional sense and gait and stance test2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID345022Binding affinity to human telomerase P2b RNA by STD NMR2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Discovery of ligands for a novel target, the human telomerase RNA, based on flexible-target virtual screening and NMR.
AID446993Anticonvulsant activity in CF1 albino mouse assessed as inhibition of maximal electric shock-induced seizure at 30 mg/kg, ip after 4 hrs2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID115839Compound was tested for the number of control mice with decreased RBC to that of number of tested mice at 100 mg/kg p.o.; 0/101998Bioorganic & medicinal chemistry letters, Jan-06, Volume: 8, Issue:1
Discovery of FR115092: a novel antinephritic agent.
AID446999Anticonvulsant activity in Sprague-Dawley rat assessed as inhibition of maximal electric shock-induced seizure at 30 mg/kg, po after 2 hrs2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID447000Anticonvulsant activity in Sprague-Dawley rat assessed as inhibition of maximal electric shock-induced seizure at 30 mg/kg, po after 4 hrs2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID446992Anticonvulsant activity in CF1 albino mouse assessed as inhibition of maximal electric shock-induced seizure at 300 mg/kg, ip after 0.5 hrs2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID117036Inhibition of proteinuria in the graft-versus-host disease mice following 100 mg/kg p.o. administration.1998Bioorganic & medicinal chemistry letters, Jan-06, Volume: 8, Issue:1
Discovery of FR115092: a novel antinephritic agent.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (25.00)18.7374
1990's1 (25.00)18.2507
2000's2 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.39

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.39 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.39)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
dapsone
[no description available]		1.9910substituted aniline;
sulfone		anti-inflammatory drug;
antiinfective agent;
antimalarial;
leprostatic drug
quetiapine
[no description available]		2.0410dibenzothiazepine;
N-alkylpiperazine;
N-arylpiperazine		adrenergic antagonist;
dopaminergic antagonist;
histamine antagonist;
second generation antipsychotic;
serotonergic antagonist
p-aminoazobenzene
p-Aminoazobenzene: Used in the form of its salts as a dye and as an intermediate in manufacture of Acid Yellow, diazo dyes, and indulines.. 4-(phenylazo)aniline : Azobenzene substituted at one of the 4-positions by an amino group. It has a role as a dye and an allergen.		1.9610
4,4'-diaminodiphenylmethane
4,4'-diaminodiphenylmethane: RN given refers to parent cpd; structure. 4,4'-diaminodiphenylmethane : An aromatic amine that is diphenylmethane substituted at the 4-position of each benzene ring by an amino group.		2.0510aromatic amineallergen;
carcinogenic agent
di-(4-aminophenyl)ether
di-(4-aminophenyl)ether: structure		2.4220aromatic ether
4,4'-thiodianiline
4,4'-thiodianiline: structure		2.4220substituted aniline
thioproperazine
thioproperazine: was heading 1963-94; use PHENOTHIAZINES to search THIOPROPERAZINE 1966-94. thioproperazine : A phenothiazine derivative in which the phenothiazine tricycle has a dimethylaminosulfonyl substituent at the 2-position and a 3-(4-methylpiperazin-1-yl)propyl group at N-10.		2.0410N-alkylpiperazine;
N-methylpiperazine;
phenothiazines;
sulfonamide		phenothiazine antipsychotic drug
4,4'-diaminoazobenzene
4,4'-diaminoazobenzene : Azobenzene substituted at each of the phenyl 4-positions by an amino group.		6.9610
4,4'-diaminobenzophenone
4,4'-diaminobenzophenone: structure in first source		2.4220
4,4'-Dihydroxybenzophenone
[no description available]		2.0410benzophenones
LSM-5894
[no description available]		2.0410organic heterobicyclic compound;
organonitrogen heterocyclic compound
ConditionIndicatedRelationship StrengthStudiesTrials
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.4220
Nephritis
Inflammation of any part of the KIDNEY.		01.9910
Anemia
A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.		01.9910
Absence Seizure
[description not available]		02.0510
Seizures
Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.		02.0510
Experimental Neoplasms
[description not available]		01.9610